Vectibix superior to bevacizumab in Japanese patients with wild-type RAS mCRC

Andrea Werblin Reid’s unflinching poetry documents the realities of cancer care, clinical trials, and loss
Her collection, “To See Yourself As You Vanish,” will be published three years after her death

I always liked poetry, but I was never a poet. I had to marry into that.

August 08, 2025

Mailing at-home test kits is more effective at getting younger adults to participate in CRC screening, UCLA study finds

Mailing a stool-based test directly to people’s homes was the most effective of four strategies for increasing colorectal cancer screening rates, according to a study by UCLA researchers aimed at identifying the best approach to promote CRC screening in adults ages 45 to 49.

August 08, 2025

Vol.51 No.31

Clinical Roundup

In phase III trial, epcoritamab regimen improves PFS in R/R follicular lymphoma

EPCORE FL-1 phase III trial results show that subcutaneous epcoritamab in combination with rituximab and lenalidomide reduced the risk of disease progression or death by 79% for patients with relapsed/refractory follicular lymphoma.

August 08, 2025

Vol.51 No.31

Clinical Roundup

Blood tests show potential for CRC detection, but follow-up falls short

About half patients completed a follow-up colonoscopy within six months of taking a blood-based colorectal cancer screening test, according to a study by investigators at UCLA Health Jonsson Comprehensive Cancer Center.

August 01, 2025

Vol.51 No.30

Clinical Conversation with The Cancer Letter

Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out

The first large cancer screening/early detection initiative to be launched in 2025—the NCI-funded Vanguard study of multi-cancer detection tests—has started accruing patients through nine sites across the U.S.

July 25, 2025

Vol.51 No.29

By Sara Willa Ernst, Jacquelyn Cobb and Paul Goldberg

City of Hope brings evidence-based approaches to integrative oncology

The landscape of cancer care is evolving rapidly, with growing recognition that optimal patient outcomes require a whole-person care approach that goes beyond cytotoxic and targeted therapies.

July 25, 2025

Vol.51 No.29

By Richard T. Lee

Vectibix superior to bevacizumab in Japanese patients with wild-type RAS mCRC

YOU MAY BE INTERESTED IN

Andrea Werblin Reid’s unflinching poetry documents the realities of cancer care, clinical trials, and loss
Her collection, “To See Yourself As You Vanish,” will be published three years after her death

Mailing at-home test kits is more effective at getting younger adults to participate in CRC screening, UCLA study finds

In phase III trial, epcoritamab regimen improves PFS in R/R follicular lymphoma

Blood tests show potential for CRC detection, but follow-up falls short

Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out

City of Hope brings evidence-based approaches to integrative oncology

Renew today!

Subscriber content

Never miss an issue!

Login

Vectibix superior to bevacizumab in Japanese patients with wild-type RAS mCRC

YOU MAY BE INTERESTED IN

Andrea Werblin Reid’s unflinching poetry documents the realities of cancer care, clinical trials, and lossHer collection, “To See Yourself As You Vanish,” will be published three years after her death

Mailing at-home test kits is more effective at getting younger adults to participate in CRC screening, UCLA study finds

In phase III trial, epcoritamab regimen improves PFS in R/R follicular lymphoma

Blood tests show potential for CRC detection, but follow-up falls short

Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out

City of Hope brings evidence-based approaches to integrative oncology

Never miss an issue!

Login

Andrea Werblin Reid’s unflinching poetry documents the realities of cancer care, clinical trials, and loss
Her collection, “To See Yourself As You Vanish,” will be published three years after her death